{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:54:44Z","timestamp":1782741284840,"version":"3.54.5"},"reference-count":75,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Effector lymphocytes are multifunctional cells of the immune system that promote cytolysis of pathogen-infected cells and nascent tumors. Tumors must learn to evade effectors and employ a wide variety of mechanisms to do so. Bispecific Abs (BsAbs) are an emerging cancer immunotherapy approach seeking to re-engage either T effectors or NK cells with malignant cells. Possessing specificity for effector cells on one end and a tumor Ag on the other, these molecules work by attracting effectors to the target cell to build an immunologic synapse and induce tumor cell killing. The BsAb blinatumomab, for example, has specificity for the T cell\u2013activating cell surface protein CD3 and the B cell Ag CD19. The only BsAb with regulatory approval currently, blinatumomab is used in the treatment of relapsed or refractory B cell acute lymphoblastic leukemia. Many additional BsAbs are in preclinical development, however, targeting many different tumor types. The variety of potential effector cells and cancer Ags, along with potential combination therapies, make BsAbs an active area of drug development. In this review, we discuss cancer recognition by the immune system and structural and mechanistic aspects of BsAbs. We summarize key steps in preclinical development and subsequent translation to medical practice. Future directions for BsAbs include combinations with a wide variety of both immunologic and nonimmunologic therapies. Defining their optimum clinical use is at early stages.<\/jats:p>","DOI":"10.4049\/jimmunol.1900496","type":"journal-article","created":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T01:25:35Z","timestamp":1563845135000},"page":"585-592","source":"Crossref","is-referenced-by-count":64,"title":["T Cell\u2013Activating Bispecific Antibodies in Cancer Therapy"],"prefix":"10.1093","volume":"203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2479-1797","authenticated-orcid":false,"given":"Asaad","family":"Trabolsi","sequence":"first","affiliation":[{"name":"Division of Hospital Medicine, Department of Medicine, University of Miami Miller School of Medicine , Miami, FL 33136"},{"name":"Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine , Miami, FL 33137"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9520-2777","authenticated-orcid":false,"given":"Artavazd","family":"Arumov","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine , Miami, FL 33137"},{"name":"Sheila and David Fuente Graduate Program in Cancer Biology, University of Miami Miller School of Medicine , Miami, FL 33136"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1842-228X","authenticated-orcid":false,"given":"Jonathan H","family":"Schatz","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine , Miami, FL 33137"},{"name":"Division of Hematology, Department of Medicine, University of Miami Miller School of Medicine , Miami, FL 33136"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,1]]},"reference":[{"key":"2025030417540660800_r1","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3389\/fimmu.2013.00371","article-title":"Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells","volume":"4","author":"Chmielewski","year":"2013","journal-title":"Front. Immunol."},{"key":"2025030417540660800_r2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/annonc\/mdx755","article-title":"Comprehensive analysis of the clinical immuno-oncology landscape","volume":"29","author":"Tang","year":"2018","journal-title":"Ann. Oncol."},{"key":"2025030417540660800_r3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"2025030417540660800_r4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"2025030417540660800_r5","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"2025030417540660800_r6","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The principles of engineering immune cells to treat cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"key":"2025030417540660800_r7","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"2025030417540660800_r8","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030417540660800_r9","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030417540660800_r10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd.2017.227","article-title":"Next generation antibody drugs: pursuit of the \u2018high-hanging fruit\u2019","volume":"17","author":"Carter","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"2025030417540660800_r11","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res."},{"key":"2025030417540660800_r12","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1073\/pnas.92.15.7021","article-title":"A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity","volume":"92","author":"Mack","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030417540660800_r13","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.1073\/pnas.0811427106","article-title":"Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10","volume":"106","author":"Klein","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"2025030417540660800_r14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","article-title":"Alternative molecular formats and therapeutic applications for bispecific antibodies","volume":"67","author":"Spiess","year":"2015","journal-title":"Mol. Immunol."},{"key":"2025030417540660800_r15","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/CJI.0b013e318156750c","article-title":"Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class","volume":"30","author":"Brischwein","year":"2007","journal-title":"J. Immunother."},{"key":"2025030417540660800_r16","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1074-7613(01)00234-5","article-title":"The immunological synapse of CTL contains a secretory domain and membrane bridges","volume":"15","author":"Stinchcombe","year":"2001","journal-title":"Immunity"},{"key":"2025030417540660800_r17","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","article-title":"Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells","volume":"43","author":"Offner","year":"2006","journal-title":"Mol. Immunol."},{"key":"2025030417540660800_r18","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-cell engagers for cancer immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol. Cell Biol."},{"key":"2025030417540660800_r19","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.20908","article-title":"Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct","volume":"115","author":"Hoffmann","year":"2005","journal-title":"Int. J. Cancer"},{"key":"2025030417540660800_r20","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood"},{"key":"2025030417540660800_r21","doi-asserted-by":"crossref","first-page":"10121","DOI":"10.1158\/0008-5472.CAN-10-1047","article-title":"Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response","volume":"70","author":"Cho","year":"2010","journal-title":"Cancer Res."},{"key":"2025030417540660800_r22","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.canlet.2016.01.001","article-title":"A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma","volume":"372","author":"Wang","year":"2016","journal-title":"Cancer Lett."},{"key":"2025030417540660800_r23","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.4049\/jimmunol.1402517","article-title":"B7H6-specific bispecific T cell engagers lead to tumor elimination and host antitumor immunity","volume":"194","author":"Wu","year":"2015","journal-title":"J. Immunol."},{"key":"2025030417540660800_r24","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","article-title":"A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes","volume":"95","author":"L\u00f6ffler","year":"2000","journal-title":"Blood"},{"key":"2025030417540660800_r25","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/sj.leu.2402890","article-title":"Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19\/anti-CD3 single-chain antibody construct","volume":"17","author":"L\u00f6ffler","year":"2003","journal-title":"Leukemia"},{"key":"2025030417540660800_r26","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.170.8.4397","article-title":"T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-\/CD3- bispecific single-chain antibody construct","volume":"170","author":"Dreier","year":"2003","journal-title":"J. Immunol."},{"key":"2025030417540660800_r27","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.4049\/jimmunol.1200341","article-title":"Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells","volume":"189","author":"Feldmann","year":"2012","journal-title":"J. Immunol."},{"key":"2025030417540660800_r28","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-15-2710","article-title":"IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function","volume":"22","author":"Vallera","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"2025030417540660800_r29","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.04.006","article-title":"A review of bispecific antibodies and antibody constructs in oncology and clinical challenges","author":"Suurs","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"2025030417540660800_r30","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1182\/blood.V98.8.2526","article-title":"Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody","volume":"98","author":"Ruf","year":"2001","journal-title":"Blood"},{"key":"2025030417540660800_r31","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/ijc.10557","article-title":"Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody","volume":"100","author":"Dreier","year":"2002","journal-title":"Int. J. Cancer"},{"key":"2025030417540660800_r32","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1182\/blood.V128.22.621.621","article-title":"Phase 1 study of REGN1979, an anti-CD20 x anti-CD3 bispecific monoclonal antibody, in patients with CD20+ B-cell malignancies previously treated with CD20-directed antibody therapy","volume":"128","author":"Bannerji","year":"2016","journal-title":"Blood"},{"key":"2025030417540660800_r33","doi-asserted-by":"crossref","first-page":"287ra70","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"2025030417540660800_r34","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"2025030417540660800_r35","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"2025030417540660800_r36","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/leu.2016.388","article-title":"A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. [Published erratum appears in 2017 Leukemia 31: 2278.]","volume":"31","author":"Hipp","year":"2017","journal-title":"Leukemia"},{"key":"2025030417540660800_r37","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood.V128.22.1147.1147","article-title":"B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) for multiple myeloma (MM): initial safety and efficacy from a phase I study","volume":"128","author":"Cohen","year":"2016","journal-title":"Blood"},{"key":"2025030417540660800_r38","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","article-title":"Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma","volume":"23","author":"Feng","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"2025030417540660800_r39","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood-2014-05-575704","article-title":"Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform","volume":"127","author":"Al-Hussaini","year":"2016","journal-title":"Blood"},{"key":"2025030417540660800_r40","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/mt.2016.116","article-title":"CD123-engager T cells as a novel immunotherapeutic for acute myeloid leukemia","volume":"24","author":"Bonifant","year":"2016","journal-title":"Mol. Ther."},{"key":"2025030417540660800_r41","first-page":"2639","article-title":"Bispecific anti-CD123 x anti-CD3 adaptir\u2122 molecules APVO436 and APVO437 have broad activity against primary human AML cells in vitro","volume":"130","author":"Godwin","year":"2017","journal-title":"Blood"},{"key":"2025030417540660800_r42","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/blood-2014-04-566737","article-title":"Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients","volume":"124","author":"Frankel","year":"2014","journal-title":"Blood"},{"key":"2025030417540660800_r43","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"2025030417540660800_r44","doi-asserted-by":"crossref","first-page":"e1450710","DOI":"10.1080\/2162402X.2018.1450710","article-title":"A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM\/CD3 T-cell engager (BiTE\u00ae) antibody construct, in patients with refractory solid tumors","volume":"7","author":"Kebenko","year":"2018","journal-title":"OncoImmunology"},{"key":"2025030417540660800_r45","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.copbio.2011.06.012","article-title":"Strategies for extended serum half-life of protein therapeutics","volume":"22","author":"Kontermann","year":"2011","journal-title":"Curr. Opin. Biotechnol."},{"key":"2025030417540660800_r46","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1517\/14712598.2016.1165661","article-title":"Half-life extended biotherapeutics. [Published erratum appears in 2016 Expert Opin. Biol. Ther. 16: 1179.]","volume":"16","author":"Kontermann","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"key":"2025030417540660800_r47","doi-asserted-by":"crossref","first-page":"25612","DOI":"10.1074\/jbc.M109.027078","article-title":"Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives","volume":"284","author":"Stork","year":"2009","journal-title":"J. Biol. Chem."},{"key":"2025030417540660800_r48","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1158\/1078-0432.CCR-05-2436","article-title":"Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer","volume":"12","author":"Kiewe","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"2025030417540660800_r49","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.25423","article-title":"The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial","volume":"127","author":"Heiss","year":"2010","journal-title":"Int. J. Cancer"},{"key":"2025030417540660800_r50","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.molimm.2005.07.034","article-title":"MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors","volume":"43","author":"Brischwein","year":"2006","journal-title":"Mol. Immunol."},{"key":"2025030417540660800_r51","doi-asserted-by":"crossref","first-page":"e13474","DOI":"10.1371\/journal.pone.0013474","article-title":"Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM\/CD3-bispecific antibody engaging human T cells","volume":"5","author":"Herrmann","year":"2010","journal-title":"PLoS One"},{"key":"2025030417540660800_r52","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.clcc.2016.07.009","article-title":"Phase 1 dose escalation study of MEDI-565, a bispecific T-cell engager that targets human carcinoembryonic antigen, in patients with advanced gastrointestinal adenocarcinomas","volume":"15","author":"Pishvaian","year":"2016","journal-title":"Clin. Colorectal Cancer"},{"key":"2025030417540660800_r53","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"key":"2025030417540660800_r54","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol."},{"key":"2025030417540660800_r55","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"2025030417540660800_r56","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"Von Stackelberg","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"2025030417540660800_r57","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"2025030417540660800_r58","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1182\/blood.V126.23.3974.3974","article-title":"Bispecific T-cell engager antibody construct blinatumomab shows durable response in a long-term follow-up analysis of 38 NHL patients treated in a phase I trial","volume":"126","author":"Dufner","year":"2015","journal-title":"Blood"},{"key":"2025030417540660800_r59","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/bloodadvances.2018019034","article-title":"Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia","volume":"2","author":"Stein","year":"2018","journal-title":"Blood Adv."},{"key":"2025030417540660800_r60","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2217\/imt-2016-0020","article-title":"Immunotherapeutic implications of IL-6 blockade for cytokine storm","volume":"8","author":"Tanaka","year":"2016","journal-title":"Immunotherapy"},{"key":"2025030417540660800_r61","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.4049\/jimmunol.1301523","article-title":"Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity?","volume":"191","author":"van der Stegen","year":"2013","journal-title":"J. Immunol."},{"key":"2025030417540660800_r62","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.24783","article-title":"Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"92","author":"Aldoss","year":"2017","journal-title":"Am. J. Hematol."},{"key":"2025030417540660800_r63","doi-asserted-by":"crossref","first-page":"S52.006","DOI":"10.1212\/WNL.82.10_supplement.S52.006","article-title":"Aphasia as a complication of CD19-targeted chimeric antigen receptor immunotherapy (S52.006)","volume":"82","author":"Kranick","year":"2014","journal-title":"Neurology"},{"key":"2025030417540660800_r64","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2018-99-118344","article-title":"Mosunetuzumab, a full-length bispecific CD20\/CD3 antibody, displays clinical activity in relapsed\/refractory B-cell non-hodgkin lymphoma (NHL): interim safety and efficacy results from a phase 1 study","volume":"132","author":"Budde","year":"2018","journal-title":"Blood"},{"key":"2025030417540660800_r65","first-page":"2556","article-title":"Baseline biomarkers influencing clinical outcomes in adults with relapsed\/refractory B-precursor acute lymphoblastic leukemia (R\/R ALL) treated with blinatumomab versus standard-of-care chemotherapy (SOC) from a randomized phase 3 study","volume":"130","author":"Wei","year":"2017","journal-title":"Blood"},{"key":"2025030417540660800_r66","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2015-06-649111","article-title":"Long-term survival and T-cell kinetics in relapsed\/refractory ALL patients who achieved MRD response after blinatumomab treatment","volume":"126","author":"Zugmaier","year":"2015","journal-title":"Blood"},{"key":"2025030417540660800_r67","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","article-title":"Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking","volume":"129","author":"Braig","year":"2017","journal-title":"Blood"},{"key":"2025030417540660800_r68","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"key":"2025030417540660800_r69","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-015-0213-6","article-title":"Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19\/CD3-bispecific T cell engager antibody blinatumomab","volume":"8","author":"K\u00f6hnke","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"2025030417540660800_r70","doi-asserted-by":"crossref","first-page":"76902","DOI":"10.18632\/oncotarget.12357","article-title":"T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80\/CD86 on leukemic blasts","volume":"7","author":"Feucht","year":"2016","journal-title":"Oncotarget"},{"key":"2025030417540660800_r71","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL","volume":"31","author":"Duell","year":"2017","journal-title":"Leukemia"},{"key":"2025030417540660800_r72","volume-title":"Blincyto (blinatumomab) [package insert]","author":"Amgen Inc.","year":"2014"},{"key":"2025030417540660800_r73","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.4049\/jimmunol.1401550","article-title":"A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy","volume":"193","author":"Golay","year":"2014","journal-title":"J. Immunol."},{"key":"2025030417540660800_r74","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/CJI.0b013e3181d75c20","article-title":"Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand\/anti-CD20 fusion proteins and anti-CD3\/anti-CD20 diabodies","volume":"33","author":"Liu","year":"2010","journal-title":"J. Immunother."},{"key":"2025030417540660800_r75","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.4143\/crt.2016.491","article-title":"Engineering of anti-CD133 trispecific molecule capable of inducing NK expansion and driving antibody-dependent cell-mediated cytotoxicity","volume":"49","author":"Schmohl","year":"2017","journal-title":"Cancer Res. Treat."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/203\/3\/585\/61887295\/ji1900496.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/203\/3\/585\/61887295\/ji1900496.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T20:15:48Z","timestamp":1741119348000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/203\/3\/585\/7952395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1900496","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2019,8,1]]}}}